4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks Investment Research9/21/2026Positive
ALNY
Alnylam Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$34.25B
P/E Ratio
44.59
EPS
$5.74
Beta
0.30
52W High
$495.55
52W Low
$197.81
50-Day MA
$244.84
200-Day MA
$307.82
Dividend Yield
—
Profit Margin
16.10%
Forward P/E
19.68
PEG Ratio
0.33
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $4.80B |
| Gross Profit (TTM) | $3.83B |
| EBITDA | $1.05B |
| Operating Margin | 17.90% |
| Return on Equity | 96.60% |
| Return on Assets | 12.30% |
| Revenue/Share (TTM) | $36.24 |
| Book Value | $10.12 |
| Price-to-Book | 24.87 |
| Price-to-Sales (TTM) | 7.13 |
| EV/Revenue | 6.58 |
| EV/EBITDA | 28.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 66.90% |
| Shares Outstanding | $133.81M |
| Float | $133.24M |
| % Insiders | 0.18% |
| % Institutions | 101.67% |
Historical Volatility
HV 10-Day
40.96%
HV 20-Day
45.87%
HV 30-Day
46.04%
HV 60-Day
82.56%
HV Rank
85.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($371.35 target)
7
Strong Buy16
Buy6
HoldLatest News
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
MarketBeat9/20/2026Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
Seeking Alpha9/17/2026Neutral
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City A live audio webcast of each pre.
Business Wire9/2/2026Neutral
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Zacks Investment Research9/1/2026Positive
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
GlobeNewsWire8/27/2026Neutral
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
RADNOR, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
GlobeNewsWire8/21/2026Neutral
Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
If you purchased or acquired stock in Alnylam and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
GlobeNewsWire8/20/2026Neutral
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of the federal securities laws.
GlobeNewsWire8/20/2026Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
GlobeNewsWire8/20/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALNY and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026